Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TPSAB1 | Q15661 | 5/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18585930 | 0.92 | DRD2 (0.57) | DRD2DRD3ALDH1A1POLBNPC1 | |
| SCHEMBL18585877 | 0.88 | PARP10 (0.48) | DRD2CHRM4NPC1RAB9A | |
| SCHEMBL4405378 | 0.87 | TPSAB1 (0.58) | TPSAB1 | |
| SCHEMBL20658773 | 0.85 | DRD2 (0.52) | DRD2DRD3ALDH1A1POLBNPC1 | |
| SCHEMBL3034379 | 0.81 | ALDH1A1 (0.47) | ALDH1A1POLBSIGMAR1CHRM4NPC1 | |
| SCHEMBL15743158 | 0.81 | CHRM4 (0.46) | DRD2ALDH1A1POLBTPSAB1SIGMAR1 | |
| SCHEMBL16957589 | 0.81 | DRD2 (0.55) | DRD2DRD3 | |
| SCHEMBL6393738 | 0.80 | HTR1A (0.52) | ALDH1A1TPSAB1 | |
| SCHEMBL11309026 | 0.80 | NAMPT (0.51) | DRD2DRD3 | |
| SCHEMBL18616729 | 0.80 | DRD2 (0.60) | DRD2DRD3TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059818-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200291015-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| US-9920075-B2 | Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170247396-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3191485-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040417-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247396-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | DRD2 2700/4885DRD3 2264/4885ALDH1A1 54/4885 |
| US-20200291015-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | MPO, NOX5, SERPINB1 | DRD2 2933/4885DRD3 2783/4885ALDH1A1 399/4885 |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | DRD2 2778/4885DRD3 2652/4885ALDH1A1 83/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | DRD2 2778/4885DRD3 2652/4885ALDH1A1 83/4885 |
| US-11059818-B2 | Triazolopyridine inhibitors of myeloperoxidase | MPO, NOX5, SERPINB1 | DRD2 2933/4885DRD3 2783/4885ALDH1A1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.